Wang Xiao-wei, Shi Xin-hui, Tong Yu-suo, Cao Xiu-feng
Department of Medical Oncology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, Jiangsu, Korea.
Department of Laboratory Medicine, Yancheng First People's Hospital, Yancheng, Jiangsu, Korea.
Yonsei Med J. 2015 Nov;56(6):1497-502. doi: 10.3349/ymj.2015.56.6.1497.
Heat shock proteins (HSPs) are highly conserved molecular chaperones. There are various studies that assess the prognostic value of HSPs in patients with esophageal cancer, but the conclusion remains controversial. This is the first meta-analysis study aiming to summarize the evidence on the suitability of HSPs to predict patients' survival.
Searching PubMed, Web of science and Medline until May 31, 2014, data were compared for overall survival in patients with down-regulated HSPs level with those with up-regulated level. We conducted a meta-analysis of 9 studies (801 patients) that correlated HSPs levels with overall survival. Data were synthesized with hazard ratios (HRs).
The estimated risk of death was 2.93-fold greater in HSP27 negative patients than HSP27 positive patients [95% confidence interval (CI), 1.12-7.62]. When limited to esophageal squamous cell carcinoma (ESCC), the risk of death in HSP27 negative patients seemed more significant (HR, 3.90; 95% CI, 2.35-6.49). Decreased expression of HSP70 was also associated with worse survival in esophageal cancer (HR, 2.83; 95% CI, 1.90-4.23) and, when limited to ESCC, HR was 3.21 (95% CI, 1.94-5.30). Data collected, however, were not sufficient to determine the prognostic value of HSP90 in patients with ESCC nor esophageal adenocarcinomas (EADC).
In this meta-analysis, reduced HSP27 and HSP70 expressions were associated with poor survival in patients with esophageal cancer, especially esophageal squamous cell carcinoma.
热休克蛋白(HSPs)是高度保守的分子伴侣。有多项研究评估了HSPs在食管癌患者中的预后价值,但结论仍存在争议。这是第一项旨在总结HSPs预测患者生存适用性证据的荟萃分析研究。
检索截至2014年5月31日的PubMed、科学网和Medline,比较HSPs水平下调患者与上调患者的总生存数据。我们对9项将HSPs水平与总生存相关联的研究(801例患者)进行了荟萃分析。数据采用风险比(HRs)进行综合分析。
HSP27阴性患者的估计死亡风险比HSP27阳性患者高2.93倍[95%置信区间(CI),1.12 - 7.62]。当仅限于食管鳞状细胞癌(ESCC)时,HSP27阴性患者的死亡风险似乎更显著(HR,3.90;95% CI,2.35 - 6.49)。HSP70表达降低也与食管癌患者较差的生存相关(HR,2.83;95% CI,1.90 - 4.23),当仅限于ESCC时,HR为3.21(95% CI,1.94 - 5.30)。然而,收集的数据不足以确定HSP90在ESCC患者和食管腺癌(EADC)患者中的预后价值。
在这项荟萃分析中,HSP27和HSP70表达降低与食管癌患者,尤其是食管鳞状细胞癌患者的不良生存相关。